GGrantIndex
Sort

30,917 grants matching tumor microenvironment

Liposomal Doxorubicin and Pluronic Combination for Cancer Therapy

$344,549
Alexander V Kabanov · Univ Of North Carolina Chapel Hill · R01 · FY2016 · CA

Liposomal Doxorubicin and Pluronic Combination for Cancer Therapy

$344,549
Alexander V Kabanov · Univ Of North Carolina Chapel Hill · R01 · FY2017 · CA

Project 3: The Role of Macrophages in Resistance to Anti-VEGF Drugs in Ovarian Cancer

$344,532
Anil K Sood · University Of Tx Md Anderson Can Ctr · P50 · FY2021 · CA

Use of Organotypic and Mammary Gland Models to Investigate the Outcomes of Clonal

$344,514
Joan Siefert Brugge · Whitehead Institute For Biomedical Res · P01 · FY2013 · CA

Integration of stromal targeting agents with immune checkpoint therapy

$344,496
Lei Zheng · Johns Hopkins University · P01 · FY2021 · CA

Integration of stromal targeting agents with immune checkpoint therapy

$344,496
Lei Zheng · Johns Hopkins University · P01 · FY2025 · CA

Targeting Stat3 to Improve Immunotherapy

$344,450
Hua E Yu · Beckman Research Institute/City Of Hope · R01 · FY2010 · CA

Targeting Stat3 to Improve Immunotherapy

$344,450
Hua E Yu · Beckman Research Institute/City Of Hope · R01 · FY2009 · CA

Developing Novel Therapeutic Approaches Targeting Macrophages in GBM

$344,441
Y. Alan Wang · Indiana University Indianapolis · R01 · FY2024 · CA

Project 1: EZH2 Inhibition to Prevent/Overcome Chemoresistance

$344,428
Robert Page Edwards · University Of Pittsburgh At Pittsburgh · P50 · FY2025 · CA

Molecular basis for HIV therapy-linked osteopenia

$344,400
Weill Medical College Of Cornell Univ · R01 · FY2005 · DK

INITIATING THE ADAPTIVE IMMUNE RESPONSE TO CANCER

$344,323
Per H. Basse · University Of Pittsburgh At Pittsburgh · P01 · FY2007 · CA

Biology Core

$344,322
Meenhard Herlyn · Wistar Institute · P01 · FY2019 · CA

Stromal Cell Function Following Chemotherapy

$344,270
Laura F Gibson · West Virginia University · R01 · FY2006 · HL

Roles of Hsp47 in breast cancer progression

$344,269
Ren Xu · University Of Kentucky · R01 · FY2018 · CA

Roles of Hsp47 in breast cancer progression

$344,269
Ren Xu · University Of Kentucky · R01 · FY2017 · CA

Roles of RORalpha in breast cancer development and progression

$344,269
Ren Xu · University Of Kentucky · R01 · FY2017 · CA

Roles of Hsp47 in breast cancer progression

$344,269
Ren Xu · University Of Kentucky · R01 · FY2020 · CA

Roles of RORalpha in breast cancer development and progression

$344,269
Ren Xu · University Of Kentucky · R01 · FY2020 · CA

Determining the mechanisms by which calorie restriction alters macrophage polarization to promote an anti-tumor environment in epithelial ovarian cancer

$344,269
Ramandeep Rattan · Henry Ford Health System · R01 · FY2021 · CA

Roles of Hsp47 in breast cancer progression

$344,269
Ren Xu · University Of Kentucky · R01 · FY2021 · CA

Determining the mechanisms by which calorie restriction alters macrophage polarization to promote an anti-tumor environment in epithelial ovarian cancer

$344,269
Ramandeep Rattan · Henry Ford Health System · R01 · FY2020 · CA

Endothelial PHD2/HIF Axis in Ischemic Kidney Injury and Inflammation

$344,250
Pinelopi P. Kapitsinou · University Of Kansas Medical Center · R01 · FY2019 · DK

ROS and Nrf2 in arsenic carcinogenesis

$344,250
Zhuo Zhang · University Of Kentucky · R01 · FY2018 · ES

Microenvironment and Arsenic Lung Tumorigenesis

$344,250
Gang Chen · University Of Kentucky · R01 · FY2018 · ES